Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK
Crossref DOI link: https://doi.org/10.1007/s40259-017-0252-3
Published Online: 2017-11-10
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Aladul, Mohammed I.
Fitzpatrick, Raymond W.
Chapman, Stephen R. http://orcid.org/0000-0002-0326-7742
License valid from 2017-11-10